

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

Questions for categories: Enlivex

- **Investment Rational**

Enlivex is a clinical stage cell therapy company developing highly-differentiated cell-therapy for the treatment of life-threatening clinical indications that are defined as "unmet medical needs", including sepsis – one of the leading causes of mortality, and oncology. Enlivex is led by a seasoned management team who founded PROLOR Biotech and led it to a successful financial exit and a partnership with Pfizer. PROLOR's lead product recently received marketing approval in Australia, Canada, Japan and the EU.

- **Business Strategy**

Enlivex is a development-stage company that focuses on clinical development in sepsis and solid tumors.

- **Core Technology**

Allocetra™ is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. As part of a new generation of companies representing the future of cell therapy – off-the-shelf, highly scalable and low COGS "beyond CAR-T" cell therapies – Enlivex is focused on a highly differentiated novel immunotherapeutic mechanism – macrophage homeostasis. Macrophage homeostasis is severely disrupted by certain diseases states, and such imbalance is critical to the progression of the diseases. Allocetra™ has the potential to introduce highly-effective, low-cost allogeneic cell therapies for life-threatening clinical indications that are defined as "unmet medical needs" through restoration of macrophage homeostasis.

- **Product Profile/Pipeline**

Indication	Mkt Size	Clinical Stage	Next Milestone	Data to date
Sepsis	\$33 Billion	Phase II	Phase II data 2022/23	Phase I/II: 100% recovery vs 27% mortality in historical control group
Oncology	\$4 Billion	Preclinical	Phase 1/2 scheduled for Q2 2022	Various preclinical models demonstrating safety and efficacy leading up to 100% complete remission

What's Next?

Completion of Phase 2 in Sepsis and commencement of global phase 3. Oncology Preclinical / Clinicals – Continue preclinical studies in different cancer types. Clinical Phase I/II trials in peritoneal metastasis with chemotherapy Q2 2022, and in advanced solid tumors as monotherapy or in combination with immune checkpoint inhibitors Q3 2022.